10x Genomics (NASDAQ:TXG) Upgraded to “Strong-Buy” at Zacks Research

10x Genomics (NASDAQ:TXG) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Thursday,Zacks.com reports.

Other analysts also recently issued research reports about the company. Deutsche Bank Aktiengesellschaft set a $14.00 target price on 10x Genomics and gave the company a “hold” rating in a research note on Friday, August 8th. Barclays reiterated an “overweight” rating and issued a $15.00 price objective (up previously from $13.00) on shares of 10x Genomics in a research report on Friday, August 8th. Bank of America raised their price objective on 10x Genomics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Thursday, June 26th. Morgan Stanley reduced their price objective on 10x Genomics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Tuesday, August 12th. Finally, Canaccord Genuity Group set a $16.00 price objective on 10x Genomics in a research report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $13.65.

10x Genomics Stock Down 2.0%

Shares of NASDAQ:TXG opened at $11.47 on Thursday. The business has a 50 day moving average price of $12.98 and a 200 day moving average price of $11.05. 10x Genomics has a twelve month low of $6.78 and a twelve month high of $18.21. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -16.39 and a beta of 2.05.

10x Genomics (NASDAQ:TXG) last announced its earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The firm had revenue of $172.91 million during the quarter, compared to the consensus estimate of $139.36 million. During the same quarter in the prior year, the company earned ($0.32) EPS. The firm’s revenue for the quarter was up 12.9% compared to the same quarter last year. 10x Genomics has set its Q3 2025 guidance at EPS. Analysts anticipate that 10x Genomics will post -1.43 EPS for the current year.

Insider Transactions at 10x Genomics

In other news, CEO Serge Saxonov sold 9,348 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $128,908.92. Following the completion of the transaction, the chief executive officer directly owned 945,892 shares of the company’s stock, valued at approximately $13,043,850.68. This represents a 0.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Adam Taich sold 22,315 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $307,723.85. Following the completion of the transaction, the chief financial officer directly owned 309,273 shares of the company’s stock, valued at approximately $4,264,874.67. The trade was a 6.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,149 shares of company stock valued at $539,865. Corporate insiders own 9.39% of the company’s stock.

Hedge Funds Weigh In On 10x Genomics

A number of hedge funds have recently modified their holdings of the stock. Lancaster Investment Management acquired a new position in shares of 10x Genomics in the 3rd quarter worth approximately $7,269,000. Grant Private Wealth Management Inc acquired a new position in shares of 10x Genomics in the 3rd quarter worth approximately $141,000. Mirador Capital Partners LP increased its holdings in 10x Genomics by 2.2% during the 3rd quarter. Mirador Capital Partners LP now owns 81,182 shares of the company’s stock valued at $949,000 after purchasing an additional 1,739 shares in the last quarter. Aaron Wealth Advisors LLC acquired a new stake in 10x Genomics during the 3rd quarter valued at $462,000. Finally, Corient Private Wealth LLC acquired a new stake in 10x Genomics during the 2nd quarter valued at $595,000. 84.68% of the stock is owned by institutional investors and hedge funds.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.